Question · asked by 1 review
Pentoxifylline vs placebo: Adverse effects
- Population
- Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination; excluding those with Behcet's disease, Reiter's syndrome, recurrent erythema multiforme, viral infection, coeliac disease, Crohn's disease, ulcerative colitis, anaemia or haematinic deficiency
- Intervention
- Pentoxifylline
- Comparison
- placebo
- Outcome
- Adverse effects
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pentoxifylline (400 mg three times daily for 60 days) vs Placebo Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and… · 60 days (plus 60-day follow-up) Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) (2012) · Cochrane All outcomes | Patients receiving pentoxifylline reported more adverse events than those in the placebo group but this was not statistically significant (69% reported adverse effects: dizziness, headaches, stomach upset, increased… | 1 study · 26 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes | 2012-06 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.